Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors.

Autor: Skelton RA; The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland., Javed A; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland., Zheng L; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland., He J; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jazyk: angličtina
Zdroj: Journal of surgical oncology [J Surg Oncol] 2017 Jul; Vol. 116 (1), pp. 55-62. Date of Electronic Publication: 2017 Jun 19.
DOI: 10.1002/jso.24642
Abstrakt: Immunotherapy has become a new modality of cancer treatment, but has had a limited success in treating PDAC. A combination approach to immunotherapy, using both immune checkpoint inhibitors and immune activating agonists, is needed, as PDAC does not respond to single-agent checkpoint inhibitors. Studies have also supported using vaccine-based therapies to prime the tumor microenvironment of PDAC with effector T-cells. Other therapeutic strategies including epigenetic agents, stroma modulators, radiotherapy, and T-cell transfer therapies may also prime the tumor microenvironment to overcome resistance to immune checkpoint inhibitors.
(© 2017 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: